Latest news with #AmitRajSinha
Mint
4 days ago
- Business
- Mint
Small-cap stock under ₹100: Sigachi Industries shares rise after THIS Capex update
Small-cap stock under ₹ 100: Sigachi Industries share price rose nearly 2 per cent in Wednesday's trading session after the company announced the opening of new R&D Center in Hyderabad. The small-cap stock opened at ₹ 54.90 apiece on Wednesday, as compared to previous close of ₹ 54.72. At 9:35 am, Sigachi Industries shares climbed to ₹ 55.62, however, the stock gave up the gains, touching an intraday low to ₹ 54.52. Pharma company said on June 18 that the company has officially opened its new R&D Center in Hyderabad—an advanced facility designed to accelerate the development of critical APIs and enhance in-house analytical capabilities. The facility is poised to play a key role in advancing Sigachi's innovation roadmap and enhancing its responsiveness to global regulatory demands, the company said in a release. 'This R&D Center is a strategic asset that will significantly strengthen our development capabilities and enable us to respond swiftly to market needs, it reflects our focus on building operational depth and creating long-term value for our customers, partners, and stakeholders in an evolving global pharmaceutical environment," said Amit Raj Sinha, Managing Director and CEO of Sigachi Industries. In a press release, the company said - The Hyderabad R&D Center is designed to: Strengthen API development and regulatory alignment by integrating advanced systems for seamless synthesis, analytics, and global filings, fuel pipeline growth through targeted investment of up to USD 1 million to support priority APIs and complex intermediates, focus resources effectively by aligning the pharma product portfolio to strategic therapeutic segments, and empower a high-impact research team to lead development efforts for global markets.
Mint
4 days ago
- Business
- Mint
Small-cap stock under ₹100: Sigachi Industries shares rise after THIS Capex update
Small-cap stock under ₹ 100: Sigachi Industries share price rose nearly 2 per cent in Wednesday's trading session after the company announced the opening of new R&D Center in Hyderabad. The small-cap stock opened at ₹ 54.90 apiece on Wednesday, as compared to previous close of ₹ 54.72. At 9:35 am, Sigachi Industries shares climbed to ₹ 55.62, however, the stock gave up the gains, touching an intraday low to ₹ 54.52. Pharma company said on June 18 that the company has officially opened its new R&D Center in Hyderabad—an advanced facility designed to accelerate the development of critical APIs and enhance in-house analytical capabilities. The facility is poised to play a key role in advancing Sigachi's innovation roadmap and enhancing its responsiveness to global regulatory demands, the company said in a release. 'This R&D Center is a strategic asset that will significantly strengthen our development capabilities and enable us to respond swiftly to market needs, it reflects our focus on building operational depth and creating long-term value for our customers, partners, and stakeholders in an evolving global pharmaceutical environment," said Amit Raj Sinha, Managing Director and CEO of Sigachi Industries. In a press release, the company said - The Hyderabad R&D Center is designed to: Strengthen API development and regulatory alignment by integrating advanced systems for seamless synthesis, analytics, and global filings, fuel pipeline growth through targeted investment of up to USD 1 million to support priority APIs and complex intermediates, focus resources effectively by aligning the pharma product portfolio to strategic therapeutic segments, and empower a high-impact research team to lead development efforts for global markets. Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Business Upturn
4 days ago
- Business
- Business Upturn
Sigachi Industries inaugurates new R&D center in Hyderabad
By Aman Shukla Published on June 18, 2025, 10:42 IST Sigachi Industries Limited has inaugurated a new research and development center in Hyderabad aimed at strengthening its pharmaceutical capabilities. The facility is focused on advancing active pharmaceutical ingredient (API) development and expanding analytical functions to meet evolving regulatory requirements. With a planned investment of up to USD 1 million, the center is expected to support the development of select priority APIs and complex intermediates. It also aligns Sigachi's pharma portfolio with key therapeutic segments to enhance operational focus. The center will be staffed by a dedicated research team tasked with developing products for global markets. Amit Raj Sinha, Managing Director and CEO of Sigachi Industries Limited, said, 'This R&D Center is a strategic asset that will significantly strengthen our development capabilities and enable us to respond swiftly to market needs, it reflects our focus on building operational depth and creating long-term value for our customers, partners, and stakeholders in an evolving global pharmaceutical environment.' Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Standard
13-06-2025
- Business
- Business Standard
Sigachi Industries Sets the Gold Standard in Microcrystalline Cellulose (MCC) and Expands Its API Leadership with New Facility
VMPL Hyderabad (Telangana) [India], June 13: Sigachi Industries Ltd., India's largest producer of Microcrystalline Cellulose (MCC), continues to set new benchmarks in global pharmaceutical excipients while strategically expanding into Active Pharmaceutical Ingredients (APIs) and specialty chemicals. With robust financial growth, a diversified portfolio, and an expanding global footprint, Sigachi is now powering ahead as a vertically integrated pharmaceutical player. In FY25, the company posted a 46.21% EBITDA growth and a 25.42% revenue surge to ₹5,003 million, driven by excipient demand, API capacity expansions, and strategic partnerships across 65+ countries. The company has delivered an EBITDA margin of 22.38% and 14.09% PAT for the same period. The year continues Sigachi's impressive performance over the last five years, where it has tripled core revenues, achieved 28% PAT CAGR, and maintained low debt and strong operating margins. "FY25 has been a transformative year for Sigachi," said Mr. Amit Raj Sinha, MD & CEO of Sigachi Industries. "We've built on our core strengths in excipients, while laying a strong foundation for future-ready API and specialty chemical capabilities. Our upcoming Orvakal facility marks the beginning of a new chapter in vertical integration, scalability, and regulatory alignment. It will anchor our next phase of growth and enhance our responsiveness to evolving global customer requirements" Strategic API Push: New Facility at Orvakal, Andhra Pradesh Sigachi has received Terms of Reference (ToR) approval from the State Environment Impact Assessment Authority (SEIAA), Andhra Pradesh, for a cutting-edge Bulk Drugs and Specialty Chemicals facility in Orvakal, Kurnool District. * Spread over 25.09 acres in Guttapadu-Orvakal node * Development starts August 1, 2025, post EC process initiation from July 15, 2025 * Will bolster Sigachi's API pipeline for regulated and semi-regulated markets * Enables faster commercialisation, seamless tech transfers, and greater proximity to regulatory jurisdictions * Reinforces India's Make in India mission through sustainable, export-ready infrastructure Global MCC Leadership "In every tablet we consume, there's a silent yet essential enabler--MCC. And Sigachi is mastering this art with unmatched precision. Our proprietary DAPOBAL® process, in-house acid recovery, and 60+ MCC grades support customers ranging from global generics to premium innovators. Our manufacturing capacity of 22,000 MTPA (operating at over 80% utilisation) (metric tonnes per annum) makes us not just India's largest, but also among the Top 5 MCC manufacturers globally. All our facilities are certified with USFDA, EDQM, EXCiPACT, ISO 9001, ISO 14001, and ISO 45001, enabling global customers to meet the highest quality and compliance standards", said Mr. Sinha, explaining more about its MCC expertise and strategy. Sigachi's dominance in MCC is rooted in its five world-class manufacturing units in Hyderabad, Dahej, Jhagadia, Raichur, and Sultanpur, with three facilities dedicated solely to MCC. Sigachi's MCC sets the global benchmark for: * Particle Size SD: less than or equal to 5 microns * Moisture Content:less than or equal to 4% * Flowability (Hausner Ratio):less than or equal to 1.20 * Tablet Hardness @10kN: greater than or equal to 7.5 kp * Disintegration Time: < 40 sec The result: faster compression, better flow, and cleaner disintegration--delivering predictability and quality that formulators can rely on. Innovation and Business Roadmap Two DSIR-certified R & D centres in Hyderabad and Dahej fuel Sigachi's innovation, backed by 7 patents, 46 trademarks, and advanced QbD development frameworks. A new API & Analytical R & D Centre in Hyderabad, launching in Q1 FY26, will centralise formulation research, data science, and excipient compatibility modelling. Sigachi's next frontier includes: * Launch of Croscarmellose Sodium (CCS) in 18 months * Co-processed MCCs like HiCel SMCC and HiCel MCG 591/611 * Entry into 3D printed pharma and nutraceuticals With capacity expansions adding 7,500 MTPA for excipients, new markets in LATAM, ASEAN, and the Middle East, and O & M contracts contributing 10% to revenue, Sigachi's growth engine is well-oiled for a 25% CAGR through FY28. With 98% ESG-compliant vendors, 100% sustainable packaging, and social impact programmes reaching over 12,600 lives, Sigachi is also a sustainability champion in pharma manufacturing. About Sigachi Industries Ltd Sigachi Industries Limited is a global player in the pharmaceutical industry dedicated to pioneering advancements in Active Pharmaceutical Ingredients (APIs), Intermediates, Excipients, vitamin-mineral blends, and Operations and Management (O & M) services. The company's diverse product portfolio is manufactured in 5 multilocational facilities, viz. Telangana, Gujarat, and Karnataka. Aligned with its ethos of customer centricity, Sigachi established subsidiaries in UAE and USA to be closer to its clients and improve responsiveness. With a strong focus on innovation, quality, and regulatory compliance, we leverage cutting-edge technology and global expertise to develop high-value pharma, food and nutrition solutions that enhance healthcare outcomes. Committed to excellence, we continuously invest in Research and Development, ensuring the highest standards of quality and safety. With 36 years of industry experience, Sigachi is a trusted partner for pharmaceutical and nutraceutical companies spread across 65+ countries. At Sigachi, we collaborate with healthcare partners, regulatory bodies, and global stakeholders to expand access to reliable, high-quality pharmaceutical ingredients.
Business Standard
13-06-2025
- Business
- Business Standard
Sigachi Industries rises after securing ToR nod from SEIAA Andhra Pradesh
Sigachi Industries added 1.15% to Rs 58.10 after the firm informed that it has secured the Terms of Reference (ToR) approval from the State Environment Impact Assessment Authority (SEIAA), Andhra Pradesh. This key approval is for its upcoming manufacturing facility dedicated to Bulk Drugs, Drug Intermediates, and Specialty Chemicals, including Active Pharmaceutical Ingredients (APIs), to be established at Orvakal in Kurnool District, Andhra Pradesh. This strategic project is proposed over 25.09 acres at Plot No. A-10, Guttapadu-Orvakal Node. The facility falls under Category B1, aligned with Schedule 5(f) of the EIA Notification, 2006, applicable to the Synthetic Organic Chemicals sector. The Environmental Clearance (EC) process for the upcoming facility is set to begin on 15 July 2025, with project development activities scheduled to commence from 1 August 2025. The project is expected to be instrumental in enhancing the companys API manufacturing capacity and strengthening its global presence. It will support the expansion of the product pipeline across regulated and semi-regulated markets, while also establishing a strategically located facility with strong export potential. Additionally, the project aligns with the Make in India initiative, promoting world-class infrastructure and sustainable manufacturing practices. Commenting on this development, Amit Raj Sinha, managing director and CEO of Sigachi Industries stated - This is a significant milestone in our journey to become a vertically integrated pharmaceutical manufacturing company. The Orvakal project will anchor our next phase of growth in APIs and specialty chemicals, helping us create scalable, sustainable, and compliant operations for global markets. At Sigachi, we are strategically positioning ourselves to cater to increasing global demand by building capacity closer to key markets and regulatory jurisdictions. The new facility will not only strengthen our product supply chain but also enable faster commercialization, seamless tech transfers, and enhanced responsiveness to evolving customer requirements. Telangana-based Sigachi Industries is engaged in the manufacturing of microcrystalline cellulose (MCC), which is widely used in the pharmaceutical, food, beverage, cosmetic, and paint industries. The most common uses of MCC are in vitamin supplements and tablets. It also acts as a bulking agent in food production. MCC is produced from refined wood pulp, which is imported by the company. The companys consolidated net profit tanked 11.8% to Rs 13.27 crore despite 23.1% rise in revenue from operations to Rs 128.20 crore in Q4 FY25 over Q4 FY24.
